12:10pm Sunday 17 December 2017

Scientists trigger self-destruct switch in lung cancer cells

“Igniting the fuse that causes lung cancer cells to self-destruct could pave the way to a completely new treatment approach.” – Professor Henning Walczak.

When healthy cells are no longer useful they initiate a chain of events culminating in self destruction. But cancer cells swerve away from this suicide path and become immortal. This means that cells grow out of control – causing tumours to form.

The Cancer Research UK team, based at the UCL Cancer Institute (link is external), has successfully fixed this fault in lung cancer cells – reprogramming the cells to self-destruct.

Using lung cancer cells and mice the scientists showed that the combination of two drugs, called TRAIL and a CDK9 inhibitor**, altered the molecular switches in the cell suicide process – forcing the cancer cells to self-destruct.

Lead researcher, Cancer Research UK scientist Professor Henning Walczak from the UCL Cancer Institute, said: “Igniting the fuse that causes lung cancer cells to self-destruct could pave the way to a completely new treatment approach  – and leave healthy cells unharmed.

“The next step of our work will see how this approach works in other cancer types, and we hope it could ultimately lead to testing this technique in trials to see if it can help patients.”

Nell Barrie, senior science information manager at Cancer Research UK, said: “This important research builds on the progress we’ve made to understand the routes cancer cells use to stay alive. Understanding and targeting these processes will move us closer to our goal of three out of four people beating cancer within the next 20 years.

“There’s an urgent need to save more lives from lung cancer and we hope these findings will one day lead to effective new treatments to help lung cancer patients and potentially those with other cancer types too.”

ENDS

For media enquiries please contact the press office on 020 3469 8300 or, out-of-hours, the duty press officer on 07050 264 059.

Notes to Editor

* You can find the abstract for this research online: http://conference.ncri.org.uk/abstracts/2014/abstracts/LB052.html (link is external)

** This drug combination is in early stage development to potentially treat non small cell lung cancer.


Share on:
or:

Health news